Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

Coronavirus company news summary: Alercell to begin distribution of Clip Covid Rapid Antigen Test in the US – Therma Bright collaborates with Afero to develop smart AcuVid™ Covid-19 rapid test

29 Apr 2021 (Last Updated April 29th, 2021 09:52)

Alercell, a US-based biotechnology company, will begin to distribute the Luminostics’ Clip Covid Rapid Antigen Test together with its antigen Covid-19 test collection kits across the US. It can rapidly test the presence of infection in the patient by looking for the antigens in the sample taken from nose or throat. The test has already received emergency use authorisation from the US Food and Drug Administration (FDA) for point-of-care use in CLIA laboratories.

Therma Bright has collaborated with Afero, an IoT platform, under a memorandum of understanding (MOU) to integrate the latter’s security and tracking technology into the 15 minute AcuVid™ Covid-19 test. The Afero-powered AcuVid™ Covid-19 test can be tracked and reported for quality assurance, shipping, logistics, and point-of-care test results and may further be approved for at-home testing. The technology developed by Afero will allow millions of test results to be shared with government bodies, workplaces, places of recreation and more.

Xtrava Health has received a $6.2m contract from the US National Institutes of Health (NIH) under the Rapid Acceleration of Diagnostics (RADxSM) initiative to accelerate the launch of its SPERA™ Covid-19 antigen test. The analytical and clinical trials expenses as well as programme management and marketing plans for the test are being supported by the RADx initiative. The Covid-19 test has been validated by Emory University, which also evaluated its clinical performance.